Australia's Vaxine eyes coronavirus vaccine trial in Philippines â DOST
In this file photo capped vials are being pictured during filling and packaging tests for the large-scale production and supply of the University of Oxford’s Covid-19 vaccine candidate, AZD1222, on a high-performance aseptic vial filling line on September 11, 2020 at the Italian biologics’ manufacturing facility of multinational corporation Catalent in Anagni, southeast of Rome, during the COVID-19 infection, caused by the novel coronavirus.
AFP/Vincenzo Pinto
Australia's Vaxine eyes coronavirus vaccine trial in Philippines — DOST
Gaea Katreena Cabico (Philstar.com) - October 26, 2020 - 5:56pm

MANILA, Philippines — Australian company Vaxine Pty Ltd has expressed interest in conducting a clinical trial of its coronavirus vaccine candidate in the country, the Department of Science and Technology said Monday.

DOST Secretary Fortunato de la Peña said the biotechnology firm based in Australia has informed the department that it is willing to conduct clinical trial and manufacturing of its potential vaccines against COVID-19 in the Philippines.

“It is quite recent in terms of expressing interest,” de la Peña said in a forum organized by the Foreign Correspondents Association of the Philippines. He did not provide other details.

According to the coronavirus vaccine tracker of the New York Times, Vaxine’s candidate vaccine combines “viral proteins with an adjuvant that stimulates the immune system.”

The Phase 2 trial for the candidate vaccine is expected to begin by the end of the year. Phase 2 studies involve up to several hundred individuals and aim to define the optimal dose and safety profile of vaccine candidates.

Earlier, the vaccine candidate of Chinese drug maker Sinovac Biotech hurdled the initial stage of screening for clinical trials in the country after passing the review of the vaccine experts panel chaired by the DOST. It is still undergoing the evaluation of the Single Joint Ethics Research Board.

The World Health Organization-led solidarity trial for COVID-19 vaccines will start in September in the Philippines. It was initially scheduled to begin by end-October.

The country is in talks with 17 companies as it seeks to source a vaccine that will help end one of the worst outbreaks in Southeast Asia.

The Philippines' COVID-19 caseload reached 371,630 Monday, with 7,039 deaths. 

COVID-19 VACCINES NOVEL CORONAVIRUS
As It Happens
LATEST UPDATE: December 2, 2020 - 3:42pm

Pharma giants Sanofi and GSK said on July 29, 2020, that they have agreed to supply Britain with up to 60 million doses of a potential COVID-19 vaccine. The agreement covers a vaccine candidate developed by France's Sanofi in partnership with the UK's GSK and is subject to a "final contract."

This thread collects some of the major developments in the search for a vaccine to ease the new coronavirus pandemic. (Main photo by AFP/Joel Saget)

December 2, 2020 - 3:42pm

Britain's approval of BioNTech-Pfizer's vaccine against COVID-19 marks a "historic moment" in the battle against the pandemic, the US pharma group's chief executive says Wednesday, after his company won the first such authorisation in the West.

"Today's Emergency Use Authorisation in the UK marks a historic moment in the fight against COVID-19," says Pfizer CEO Albert Bourla.

The US company and Germany's BioNTech adds that they expected further regulatory decisions from other countries "in the coming days and weeks". —  AFP

December 2, 2020 - 3:20pm

UK approves Pfizer-BioNTech vaccine for rollout from "next week".

Britain on Wednesday becomes the first country to approve Pfizer-BioNTech's COVID-19 vaccine for general use and says it would be introduced next week.

"The government has today accepted the recommendation from the independent Medicines and Healthcare products Regulatory Agency (MHRA) to approve Pfizer-BioNTech's Covid-19 vaccine for use," the department of health says in a statement.

"The vaccine will be made available across the UK from next week," the statement says, with priority groups including care home residents, health and care staff. —  AFP

December 2, 2020 - 2:41pm

President Rodrigo Duterte grants authority to the Food and Drug Administration to issue emergency use authorization for COVID-19 vaccines, Executive Secretary Salvador Medialdea says.

Duterte's Executive Order 121 also allows FDA to release emergency use authorization for COVID-19 drugs, prescribing conditions and for other purposes.

December 2, 2020 - 8:15am

The Pfizer and Moderna COVID-19 vaccines could be approved in a matter of weeks, but who in the United States will get them first? 

A high level panel of US experts on Tuesday voted that health care workers and residents of long-term care facilities should be prioritized in the first phase.

"I believe that my vote reflects maximum benefits, minimum harm, promoting justice and mitigating the health inequalities that exist, with regard to distribution of this vaccine," said Jose Romero, chair of the Advisory Committee on Immunization Practices at the Centers for Disease Control and Prevention.

As the sequence continues though, US experts may differ from other countries in prioritizing "critical workers" who keep society running — potentially even before people at highest risk. — AFP
 

December 1, 2020 - 8:45pm

The European Medicines Agency (EMA) on Tuesday says it would hold an extraordinary meeting on December 29 "at the latest" to consider emergency approval for a COVID-19 vaccine developed by Germany's BioNTech and US giant Pfizer.

"If the data submitted are robust enough to conclude on the quality, safety and effectiveness of the vaccine, EMA... will conclude its assessment during an extraordinary meeting scheduled for 29 December at the latest," the EU regulator says in a statement. 

Pfizer and BioNTech earlier announced they had formally applied for conditional EU approval for their jab, following a similar request in the United States. — AFP

Philstar
  • Latest
  • Trending
Latest
Are you sure you want to log out?
X
Login

Philstar.com is one of the most vibrant, opinionated, discerning communities of readers on cyberspace. With your meaningful insights, help shape the stories that can shape the country. Sign up now!

FORGOT PASSWORD?
SIGN IN
or sign in with